{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:06:03Z","timestamp":1780470363059,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","award":["2017-I2M-1-001"],"award-info":[{"award-number":["2017-I2M-1-001"]}]},{"name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","award":["2017-I2M-2-001"],"award-info":[{"award-number":["2017-I2M-2-001"]}]},{"name":"The National Key Research and Development program of China: The cluster construction of human genetic resource Bio-bank in north China","award":["2016YFC1201703"],"award-info":[{"award-number":["2016YFC1201703"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.humpath.2018.10.041","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T17:29:51Z","timestamp":1545931791000},"page":"155-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["PD-L1 expression and association with malignant behavior in pheochromocytomas\/paragangliomas"],"prefix":"10.1016","volume":"86","author":[{"given":"Dan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2018.10.041_bb0005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2018.10.041_bb0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.humpath.2018.10.041_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1358332","article-title":"Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: relationship with the hypoxic response, immune evasion and malignant behavior","volume":"6","author":"Pinato","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.humpath.2018.10.041_bb0020","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.humpath.2018.10.041_bb0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs: from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.humpath.2018.10.041_bb0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.humpath.2018.10.041_bb0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.humpath.2018.10.041_bb0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc3973","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","volume":"15","author":"Melero","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2018.10.041_bb0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.humpath.2018.10.041_bb0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coi.2015.01.006","article-title":"The evolution of checkpoint blockade as a cancer therapy: what\u2019s here, what\u2019s next?","volume":"33","author":"Shin","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.humpath.2018.10.041_bb0055","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","article-title":"Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure)","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2018.10.041_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1061186X.2018.1521414","article-title":"Development of small-molecule immune checkpoint inhibitors of PD-1\/PD-L1 as a new therapeutic strategy for tumour immunotherapy","author":"Li","year":"2018","journal-title":"J Drug Target"},{"key":"10.1016\/j.humpath.2018.10.041_bb0065","doi-asserted-by":"crossref","first-page":"21794","DOI":"10.18632\/oncotarget.15585","article-title":"Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors","volume":"8","author":"Chovanec","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2018.10.041_bb0070","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1213934","article-title":"Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: implications for immunotherapy","volume":"5","author":"Pinato","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.humpath.2018.10.041_bb0075","first-page":"167","article-title":"Detection of HPV E6\/E7 mRNA in clinical samples using RNA in situ hybridization","volume":"2018","author":"Pandey","year":"1726","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.humpath.2018.10.041_bb0080","doi-asserted-by":"crossref","first-page":"115179","DOI":"10.18632\/oncotarget.23112","article-title":"High protein and mRNA expression levels of TUBB3 (class III ss-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas","volume":"8","author":"Loeser","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2018.10.041_bb0085","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.18632\/oncotarget.23827","article-title":"Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples","volume":"9","author":"Soo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2018.10.041_bb0090","doi-asserted-by":"crossref","first-page":"46209","DOI":"10.1038\/srep46209","article-title":"PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non\u2013small cell lung cancer","volume":"7","author":"Shi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2018.10.041_bb0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.prp.2010.01.007","article-title":"Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma","volume":"206","author":"Tavangar","year":"2010","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.humpath.2018.10.041_bb0100","series-title":"WHO classification of tumours: pathology and genetics of tumours of endocrine organs","author":"Lloyd","year":"2017"},{"key":"10.1016\/j.humpath.2018.10.041_bb0105","first-page":"EC01-4","article-title":"Risk stratification in paragangliomas with PASS (Pheochromocytoma of the Adrenal Gland Scaled Score) and immunohistochemical markers","volume":"10","author":"Kulkarni","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.humpath.2018.10.041_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168413","article-title":"Disentangling of malignancy from benign pheochromocytomas\/paragangliomas","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2018.10.041_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121361","article-title":"Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas","volume":"10","author":"Oudijk","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2018.10.041_bb0120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1464-410x.2001.00102.x","article-title":"Tumour angiogenesis and Ki-67 expression in phaeochromocytoma","volume":"87","author":"Ohji","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.humpath.2018.10.041_bb0125","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10735-018-9777-0","article-title":"VEGFA and VEGFR2 RNAscope determination in gastric cancer","volume":"49","author":"Tamma","year":"2018","journal-title":"J Mol Histol"},{"key":"10.1016\/j.humpath.2018.10.041_bb0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/15384047.2018.1423919","article-title":"PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer","volume":"19","author":"Ren","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.humpath.2018.10.041_bb0135","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/modpathol.2017.188","article-title":"Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression","volume":"31","author":"Tretiakova","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2018.10.041_bb0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12672-017-0284-7","article-title":"Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas","volume":"8","author":"Asai","year":"2017","journal-title":"Horm Cancer"},{"key":"10.1016\/j.humpath.2018.10.041_bb0145","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10571-018-0579-4","article-title":"Continued tumor reduction of metastatic pheochromocytoma\/paraganglioma harboring succinate dehydrogenase subunit b mutations with cyclical chemotherapy","volume":"38","author":"Jawed","year":"2018","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.humpath.2018.10.041_bb0150","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2018.10.041_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci Signal"},{"key":"10.1016\/j.humpath.2018.10.041_bb0160","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response?","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Front Immunol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718304982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718304982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T21:14:06Z","timestamp":1555103646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817718304982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":32,"alternative-id":["S0046817718304982"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2018.10.041","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 expression and association with malignant behavior in pheochromocytomas\/paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2018.10.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}